"I love Tricida | Working to Turn the Tide on Metabolic Acidosis"
www.tricida.com VS www.gqak.com
2022-05-16 18:39:09
CompanyCKD & Metabolic AcidosisVeverimerInvestorsNewsCareers COMPANYOverviewManagementBoard of DirectorsAdvisory BoardsCompliance and EthicsWe CareCKD & METABOLIC ACIDOSISVEVERIMEROverviewExpanded AccessINVESTORSOverviewPresentations & EventsSEC FilingsGovernanceAnnual Report and ProxyStockAnalyst CoverageContact IRNEWSCAREERSJob OpportunitiesContact Our CompanyTricida, Inc., is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density.Learn More Chronic Kidney Disease & Metabolic AcidosisCKD is a serious condition characterized by the gradual loss of essential kidney functions over time. In patients with CKD, normal fluid and electrolyte balance can no longer be maintained…Learn MoreVeverimer (Also known as TRC101)Our investigational drug, veverimer (also known as TRC101), is a novel, non-absorbed polymer that is designed to bind…Learn More News May 10, 2022 Tricida Announces First Quarter 2022 Financial Results Learn More Careers/ContactTricida, Inc., is a pharmaceutical company focused on the development…Learn More Metabolic Acidosis is a serious disease that afflicts millions of Americans Focused on veverimer, a non-absorbed drug candidate designed to treat metabolic acidosis in patients with chronic kidney disease Company About CKD & Metabolic Acidosis Veverimer Investors News Contact Careers Privacy Policy TermsForward Looking Statement Site Map © Tricida, Inc. All rights reserved.
